Overall, the distribution of patient-reported acceptability and tolerability responses was significantly higher
for P/MC compared with 2L PEG-3350 and bisacodyl tablets (P ! .0001). Important differences between the
2 treatment arms are summarized in Figure 3. Briefly, a greater proportion of patients receiving P/MC rated the
treatment regimen as very easy or easy to consume (89.4% vs 29.1%) and as having an excellent or good
taste (73.9% vs 21.5%) compared with patients in the 2L PEG-3350 and bisacodyl tablets treatment arm. Also, compared
with patients receiving 2L PEG-3350 and bisacodyl tablets, patients in the P/MC treatment arm rated the overall
treatment experience as excellent or good (92.0% vs 59.5%) and would use the same regimen for a future colonoscopy